Thrombosis during infancy and childhood: What we know and what we do not know

Janna M. Journeycake, Marilyn J. Manco-Johnson

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

The mean age of adults who have venous thrombosis is the sixth to eighth decade of life. Many adults who have thrombosis have significant underlying illnesses (eg, cardiac disease, cancer) that decrease life expectancy. Conversely, despite underlying illnesses, children have a greater chance to survive and are expected to live 6 to 8 decades following an episode of venous or arterial thrombosis. The disproportionate benefits of preventing thrombosis and its sequelae in pediatric patients are evident. Therefore, it is necessary to develop appropriate strategies for diagnosis and management of thromboembolic events in children and to understand their acute and long-term effects. There are many unanswered questions, so clinical trials are being designed to help study these important issues.

Original languageEnglish (US)
Pages (from-to)1315-1338
Number of pages24
JournalHematology/Oncology Clinics of North America
Volume18
Issue number6 SPEC.ISS.
DOIs
StatePublished - Dec 2004

Fingerprint

Thrombosis
Heart Neoplasms
Life Expectancy
Venous Thrombosis
Heart Diseases
Clinical Trials
Pediatrics

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Thrombosis during infancy and childhood : What we know and what we do not know. / Journeycake, Janna M.; Manco-Johnson, Marilyn J.

In: Hematology/Oncology Clinics of North America, Vol. 18, No. 6 SPEC.ISS., 12.2004, p. 1315-1338.

Research output: Contribution to journalArticle

@article{92b816fc6f454827a06fdde7981954de,
title = "Thrombosis during infancy and childhood: What we know and what we do not know",
abstract = "The mean age of adults who have venous thrombosis is the sixth to eighth decade of life. Many adults who have thrombosis have significant underlying illnesses (eg, cardiac disease, cancer) that decrease life expectancy. Conversely, despite underlying illnesses, children have a greater chance to survive and are expected to live 6 to 8 decades following an episode of venous or arterial thrombosis. The disproportionate benefits of preventing thrombosis and its sequelae in pediatric patients are evident. Therefore, it is necessary to develop appropriate strategies for diagnosis and management of thromboembolic events in children and to understand their acute and long-term effects. There are many unanswered questions, so clinical trials are being designed to help study these important issues.",
author = "Journeycake, {Janna M.} and Manco-Johnson, {Marilyn J.}",
year = "2004",
month = "12",
doi = "10.1016/j.hoc.2004.07.001",
language = "English (US)",
volume = "18",
pages = "1315--1338",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6 SPEC.ISS.",

}

TY - JOUR

T1 - Thrombosis during infancy and childhood

T2 - What we know and what we do not know

AU - Journeycake, Janna M.

AU - Manco-Johnson, Marilyn J.

PY - 2004/12

Y1 - 2004/12

N2 - The mean age of adults who have venous thrombosis is the sixth to eighth decade of life. Many adults who have thrombosis have significant underlying illnesses (eg, cardiac disease, cancer) that decrease life expectancy. Conversely, despite underlying illnesses, children have a greater chance to survive and are expected to live 6 to 8 decades following an episode of venous or arterial thrombosis. The disproportionate benefits of preventing thrombosis and its sequelae in pediatric patients are evident. Therefore, it is necessary to develop appropriate strategies for diagnosis and management of thromboembolic events in children and to understand their acute and long-term effects. There are many unanswered questions, so clinical trials are being designed to help study these important issues.

AB - The mean age of adults who have venous thrombosis is the sixth to eighth decade of life. Many adults who have thrombosis have significant underlying illnesses (eg, cardiac disease, cancer) that decrease life expectancy. Conversely, despite underlying illnesses, children have a greater chance to survive and are expected to live 6 to 8 decades following an episode of venous or arterial thrombosis. The disproportionate benefits of preventing thrombosis and its sequelae in pediatric patients are evident. Therefore, it is necessary to develop appropriate strategies for diagnosis and management of thromboembolic events in children and to understand their acute and long-term effects. There are many unanswered questions, so clinical trials are being designed to help study these important issues.

UR - http://www.scopus.com/inward/record.url?scp=7044224583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044224583&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2004.07.001

DO - 10.1016/j.hoc.2004.07.001

M3 - Article

C2 - 15511618

AN - SCOPUS:7044224583

VL - 18

SP - 1315

EP - 1338

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6 SPEC.ISS.

ER -